Dr Ross Macdonald, Cynata’s Chief Executive Officer, said: “We operate in a highly dynamic environment and the situation around the MEND clinical trial has certainly exhibited a fast-moving landscape. The widespread uptake of COVID-19 and influenza vaccines, availability of new antiviral drugs, along with vastly improved patient management practices in our target population, have had very significant effects on the trial and the availability of eligible patients. These effects have had to be factored into our plans to ensure an optimal risk profile and allocation of resources across our clinical pipeline. Our strategic portfolio review was intended to ensure that we focus the application of resources on only the most viable opportunities and continuing to pursue the MEND trial no longer had alignment with that goal. The decision allows us to refocus our resources on, and maintain our commitment to, our other promising clinical programs.”
12 August 2022.
CYP Price at posting:
32.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)